http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020201073-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df02dc2eab1779ebc7dfb5accf94318b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed3c2f63a5b1c705b1b389a6f1f1f7c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 |
| filingDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_792142b793d9559285b133b29328a88c |
| publicationDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020201073-A1 |
| titleOfInvention | Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders |
| abstract | The invention relates to a PI3K inhibitor for use in the treatment of keloid, hypertrophic, bum scars and/or hyperpigmentation disorders in a subject in need thereof. 19 patients underwent multiple surgeries before receiving BYL719. These surgery procedures led to a certain number of severe hypertrophic and keloid scars. Inventors observed that during treatment with oral BYL719, the length, the area and the thickness of the different scars were dramatically reducing without additional treatment. Furthermore, they observed a spontaneous that the nevi were spontaneously decolorating with BYL719. Nevus color was evaluated using an arbitrary visual scale ranging from (5: dark color to 1: normal skin color). This new approach with either BYL719 alone or in combination with other therapeutics seem to be very promising in patients with keloid, hypertrophic, and/or burn scars. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022255738-A1 |
| priorityDate | 2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 348.